These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26066608)

  • 41. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
    Currie AJ; Prosser A; McDonnell A; Cleaver AL; Robinson BW; Freeman GJ; van der Most RG
    J Immunol; 2009 Dec; 183(12):7898-908. PubMed ID: 20007574
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A; Riva A; Cooksley H; Phillips S; Puranik S; Nathwani A; Brett S; Chokshi S; Naoumov NV
    Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway.
    Porakishvili N; Kardava L; Jewell AP; Yong K; Glennie MJ; Akbar A; Lydyard PM
    Haematologica; 2004 Apr; 89(4):435-43. PubMed ID: 15075077
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.
    Hou FQ; Wu XJ; Wang Y; Chen J; Liu YZ; Ren YY; Song G; Ding YP; Yu M; Wang GQ
    J Viral Hepat; 2013 Apr; 20 Suppl 1():18-26. PubMed ID: 23458521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
    Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
    PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CD8+ T-cells Co-expressing PD-1 and TIGIT Are Highly Frequent in Chronic Lymphocytic Leukemia.
    Hajiasghar-Sharbaf R; Asgarian-Omran H; Valadan R; Hossein-Nattaj H; Shekarriz R; Zaboli E; Janbabaei G; Tehrani M
    Iran J Allergy Asthma Immunol; 2021 Dec; 20(6):751-763. PubMed ID: 34920658
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Expression and Clinical Significance of Helper T Cells 9 and Its Sytokines Interleukin 9 in Chronic Lymphocytic Leukemia].
    Shabaaiti T; Pang NN; Xierenguli A; Nazhakaiti Y; Guo S; Zhang RR; Gong S; Qu JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1663-1669. PubMed ID: 38071043
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PD-1 AND TIM-3 BLOCKING CANNOT ENHANCE APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDUCED BY PERIPHERAL BLOOD CD8
    Jafarkhani S; Hossein-Nataj H; Eslami-Jouybari M; Ghoreishi M; Asgarian-Omran H
    Exp Oncol; 2022 Dec; 44(4):287-294. PubMed ID: 36811540
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer.
    Takano S; Saito H; Ikeguchi M
    Surg Today; 2016 Nov; 46(11):1341-7. PubMed ID: 26801344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PERIOPERATIVE PROGRAMMED DEATH 1 EXPRESSION ON CD4+ T CELLS PREDICTS THE INCIDENCE OF POSTOPERATIVE INFECTIOUS COMPLICATIONS.
    Kubo T; Ono S; Miyazaki H; Saitoh D; Yamamoto J; Hase K
    Shock; 2015 Oct; 44(4):323-9. PubMed ID: 26052961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis.
    Li S; Liao W; Chen M; Shan S; Song Y; Zhang S; Song H; Yuan Z
    Inflammation; 2014 Feb; 37(1):116-21. PubMed ID: 24062057
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
    Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
    J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The expression of Tim-3 in peripheral blood of ovarian cancer.
    Wu J; Liu C; Qian S; Hou H
    DNA Cell Biol; 2013 Nov; 32(11):648-53. PubMed ID: 24007284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme.
    Goods BA; Hernandez AL; Lowther DE; Lucca LE; Lerner BA; Gunel M; Raddassi K; Coric V; Hafler DA; Love JC
    PLoS One; 2017; 12(9):e0181538. PubMed ID: 28880903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Increased Expression of Programmed Cell Death-1 in Regulatory T Cells of Patients with Severe Sepsis and Septic Shock: An Observational Clinical Study.
    Liu Q; An L; Qi Z; Zhao Y; Li C
    Scand J Immunol; 2017 Nov; 86(5):408-417. PubMed ID: 28888058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationships between T-lymphocytes and physical function in adults with chronic lymphocytic leukemia: Results from the HEALTH4CLL pilot study.
    Crane JC; Gordon MJ; Basen-Engquist K; Ferrajoli A; Markofski MM; Lee CY; Fares S; Simpson RJ; LaVoy EC
    Eur J Haematol; 2023 Jun; 110(6):732-742. PubMed ID: 36946440
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.
    Yang ZZ; Grote DM; Ziesmer SC; Xiu B; Novak AJ; Ansell SM
    Blood Cancer J; 2015 Feb; 5(2):e281. PubMed ID: 25700246
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia.
    Gonzalez-Rodriguez AP; Contesti J; Huergo-Zapico L; Lopez-Soto A; Fernández-Guizán A; Acebes-Huerta A; Gonzalez-Huerta AJ; Gonzalez E; Fernandez-Alvarez C; Gonzalez S
    Leuk Lymphoma; 2010 Oct; 51(10):1829-36. PubMed ID: 20846097
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.
    Vodárek P; Écsiová D; Řezáčová V; Souček O; Šimkovič M; Vokurková D; Belada D; Žák P; Smolej L
    Cancer Med; 2023 Mar; 12(6):6956-6970. PubMed ID: 36440594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human CXCR5
    Hofland T; Martens AWJ; van Bruggen JAC; de Boer R; Schetters S; Remmerswaal EBM; Bemelman FJ; Levin MD; Bins AD; Eldering E; Kater AP; Tonino SH
    Eur J Immunol; 2021 Mar; 51(3):703-713. PubMed ID: 33098668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.